Better quality pancreatic cancer care received in metropolitan and higher socio-economic areas

Published: Comments:
Community Health & Wellness Science & Research

This is an archived copy of an article. It is online for informational purposes only.
Social:   
Rachel Neale

QIMR Berghofer researchers have found that pancreatic cancer patients living in metropolitan centres and areas with a high socio-economic status receive better-quality medical care, which is associated with improved survival.

The study involved 1,571 patients from Queensland and New South Wales who were diagnosed with pancreatic cancer between July 2009 and July 2011. It was a collaboration with researchers from Cancer Council NSW and various hospitals in Queensland and NSW.

Researchers gave the patients a quality-of-care score based on factors including the access they had to different services, the treatment they were offered, what sort of specialist doctor they were seen by, whether they participated in a clinical trial, and whether they were reviewed at a multi-disciplinary team meeting.

The head of QIMR Berghofer’s Cancer Aetiology and Prevention Laboratory, Associate Professor Rachel Neale, said it was believed to be the first time Australian researchers had calculated a single score to describe the quality of the care provided to pancreatic cancer patients.

“We found that patients living in major cities had scores 11 per cent higher than those living in rural areas,” Associate Professor Neale said.

“Patients living in areas with the highest socio-economic status had scores eight per cent higher than those living in areas with the lowest socio-economic status. And younger patients scored better than older patients.

“Finally, we found that patients who were treated in hospitals that see a large number (30 or more) of pancreatic cancer patients per year received higher scores than those who were treated in hospitals that saw a small number (fewer than 10) each year.”

Significantly, patients with higher scores lived for longer than patients with lower scores.

Associate Professor Neale said the differences in scores were partly explained by the availability of specialist doctors and multi-disciplinary teams in hospitals and in areas of residence.

“Patients who were treated in hospitals that care for a lot of pancreatic cancer patients were more likely to be seen by a specialist surgeon, rather than a general surgeon, and were more likely to be treated by a multi-disciplinary team. These hospitals are usually located in metropolitan centres,” she said.

“Pancreatic cancer is very difficult to treat and requires highly specialised care. Our results show that receiving high-quality medical care does make a difference to a patient’s outcome.

“These results suggest that strategies should be developed to ensure that all patients with pancreatic cancer have the opportunity to be evaluated by and treated in, or in conjunction with, major hospitals that treat the cancer often.”

Pancreatic cancer is the 10th most common cancer in Australia and the fourth most common cause of cancer-related deaths. Only 20 per cent of patients survive for 12 months after being diagnosed.

The study has been published today in the Medical Journal of Australia. It was funded by the National Health and Medical Research Council.

 
QIMR Berghofer Medical Research Institute :
PO Royal Brisbane Hospital, Brisbane, QLD, 4029, Brisbane
07 3845 3752
QIMR Berghofer Medical Research Institute
Showing 10+ recent articles for this business
Aspirin and similar drug use linked to lower endometrial cancer risk in overweight women 07 March 2019 | A study by QIMR Berghofer researchers has found that overweight and obese women who take aspirin at least once a week may reduce their risk of developing endometrial cancer (cancer of the womb). More information...
Safer bone marrow transplants for blood cancer patients a step closer 15 February 2019 | Queensland researchers have conducted Australia’s first clinical trial using genetically engineered immune cells to make bone marrow transplantation for blood cancer safer. More information...
New study finds hysterectomies reduce the risk of ovarian cancer in some women 12 February 2019 | A new study by QIMR Berghofer researchers has found women who suffer from endometriosis or uterine fibroids and who undergo hysterectomies have a significantly lower risk of developing ovarian cancer than those... More information...
Australia’s melanoma rates once again highest in the world 07 February 2019 | Australia has regained the unenviable title of having the world’s highest rates of invasive melanoma. More information...
Peak health bodies recommend new approach to sunscreen use 25 January 2019 | The peak bodies responsible for sun safety advice in Australia and New Zealand have adopted a new policy on sunscreen use, recommending that people apply it daily as part of a regular morning routine. More information...
Study gives hope for preventing life-threatening viral infections in transplant patients 18 January 2019 | Australian researchers have made a breakthrough in understanding how a common herpes virus reactivates and causes life-threatening complications in patients with compromised immune systems. More information...
Queensland scientists create functioning human muscle in a dish 10 December 2018 | QIMR Berghofer researchers have created functioning miniature human skeletal muscle – a move that will accelerate research into muscle disease and treatments. More information...
Discovery holds promise for a new oesophageal cancer screening test 04 December 2018 | One of Australia’s most deadly cancers could in future be detected earlier, and with a simple blood test, thanks to research from QIMR Berghofer Medical Research Institute. More information...
QIMR Berghofer helps map the genetic makeup of disease-spreading mosquito 22 November 2018 | QIMR Berghofer scientists have helped map the most complete genetic picture of the potentially deadly Aedes aegypti mosquito. More information...
Clinical trial finds new immunotherapy improves MS symptoms 20 November 2018 | A world-first clinical trial of a new cellular immunotherapy for multiple sclerosis (MS) has found that it improved symptoms and quality of life for the majority of patients. More information...



Social:   
comments powered by Disqus

All articles submitted by third parties or written by My Sunshine Coast come under our Disclaimer / Terms of Service